Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Melanoma 7Prostatic Neoplasms 5Ovarian Neoplasms 5Neoplasm Metastasis 5Recurrence 4Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Lung Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Mycosis Fungoides 1Multiple Myeloma 1

Interventions

Nivolumab 7toripalimab 5Injections 5tislelizumab 3pembrolizumab 3spartalizumab 2Paclitaxel 2Ipilimumab 2Gemcitabine 2Cisplatin 2zimberelimab 1ulocuplumab 1sotorasib 1sintilimab 1osimertinib 1famitinib 1donafenib 1cemiplimab 1binimetinib 1avelumab 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Taxes 1SHR-1701 1Oxaliplatin 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1LY-2157299 1Immunotherapy, Adoptive 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumor × cemiplimab × Clear all
NCT06384807 2026-03-11

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Biohaven Pharmaceuticals, Inc.

Phase 1/2 Recruiting
500 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡